55.20CHF-0.90%Mkt Cap: 683.08M CHFP/E: 17.58Last update: 2026-05-13
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intrav…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)17.58
P/E (Forward)13.25
PEG-0.08
P/B5.29
P/S2.93
EV/EBITDA11.22
EV/Revenue2.61
EPS (TTM)3.14
EPS (Forward)4.16
Cash Flow & Leverage
FCF Yield7.20%
FCF Margin21.15%
Operating CF62.09M CHF
CapEx (TTM)2.86M CHF
Net Debt/EBITDA-1.31
Net Debt-70.58M CHF
Technical
SMA 5053.75 (+2.7%)
SMA 20051.50 (+7.2%)
Beta0.41
S&P 52W Chg24.23%
Avg Vol (30d)29.07K
Avg Vol (10d)24.93K
Technical Indicators
RSI (14)55.3
MACD0.2992
MACD Signal0.2143
MACD Hist.+0.0849
BB Upper56.86 CHF
BB Middle54.73 CHF
BB Lower52.60 CHF
BB Width7.77%
ATR (14)1.455 CHF
Vol Ratio (20d)0.70x
52W Range
42.7573% of range59.70
52W High59.70 CHF
52W Low42.75 CHF
Profitability
Gross Margin83.08%
EBITDA Margin23.27%
Profit Margin17.32%
Oper. Margin21.70%
ROE31.45%
ROA14.27%
Revenue Growth-2.90%
Earnings Growth-55.20%
Balance Sheet
Debt/Equity0.70
Current Ratio5.12
Quick Ratio4.53
Book Value/Sh10.41 CHF
Cash/Share13.00 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 11, 2013
Pay Date—
Ownership
Shares Out.12.37M
Float12.21M
Insiders0.62%
Institutions29.79%
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)89.90 CHF
Target Range59.40 CHF – 120.00 CHF
# Analysts6
Company
Market Cap683.08M CHF
Enterprise Value606.69M CHF
Revenue (TTM)232.38M CHF
Gross Profit193.06M CHF
Net Income (TTM)40.24M CHF
Revenue/Share18.98 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees189
Last Price55.20 CHF
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0011432447